title: Anti-TNFalpha therapy--killing two birds with one stone?
authors.affiliation: Department of Immunobiology, King's College, Guy's Hospital, London, UK.
authors.forename: Sefina
authors.initials: S
authors.lastname: Arif
authors.forename: Patricia
authors.initials: P
authors.lastname: Cox
authors.forename: Behdad
authors.initials: B
authors.lastname: Afzali
authors.forename: Giovanna
authors.initials: G
authors.lastname: Lombardi
authors.forename: Robert I
authors.initials: RI
authors.lastname: Lechler
authors.forename: Mark
authors.initials: M
authors.lastname: Peakman
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Mirenda
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab